Spotlight On... Google med tech play Verily to relocate to former Onyx space in South SF; AdvaMed appoints former BIO COO in top spot; Alung raises $12M for artificial lung; and more...

Verily (formerly Google Life Sciences) demonstrated its increased independence from parent company Alphabet ($GOOG) by leasing a new 400,000-square-foot, South San Francisco facility from Amgen ($AMGN). The unit plans to begin shifting its 400 employees from Mountain View, CA, by the end of the year. Amgen inherited the facility when it acquired oncology-focused Onyx Pharmaceuticals for $9.7 billion in 2013. More

@FierceMedDev: FDA warns two diagnostics players for marketing unapproved tests. More | Follow @FierceMedDev

@EmilyWFierce: AstraZeneca bags EU approval for gout drug Zurampic as it eyes $500M in sales. Article | Follow @EmilyWFierce

> The Advanced Medical Technology Association (AdvaMed) has named Scott Whitaker as president and CEO; he was previously the COO of the Biotechnology Innovation Organization (BIO). The appointment is effective as of April 4. More

> A Georgia federal jury ruled against Johnson & Johnson ($JNJ) with a $4.4 million verdict in a pelvic mesh implant case. More

> Alung Technologies has reportedly raised $12 million to get its artificial lung before the FDA. It plans a U.S. trial to start later this year with an FDA decision targeted for 2018 or 2019. More

Biotech News

@FierceBiotech: Novartis' blood cancer drug bags a 'breakthrough' tag on the way to FDA filing. Story | Follow @FierceBiotech

@JohnCFierce: ICYMI: Adimab issues a challenge: Use new tech to build a rapid-response R&D platform for infectious diseases. News | Follow @JohnCFierce

@DamianFierce: Voice actors share how they deliver drug ad warnings without sounding, well, scary. More | Follow @DamianFierce

> New Canadian biotech aims for a novel approach to blood cancer, rare disease. Article

> Bottom-dwelling biotech Hemispherx dumps its CEO and vows to stamp out nepotism. Story

Pharma News

@FiercePharma: NEJM study finds Actos holds off repeat strokes, heart attacks in insulin-resistant patients. Story | Follow @FiercePharma

@EricPFierce: New York gives $200M for Athenix to build Buffalo plant. Company pledges 900 jobs over 10 years. Story | Follow @EricPFierce

@CarlyHFierce: #ICYMI yesterday: U.K. cost gatekeepers say 'show me' to Alexion's new rare disease med Kanuma. Item | Follow @CarlyHFierce

> FDA approves UCB drug for treating epileptic seizures. Story

> Teva offers up concessions for quick EU review of Allergan deal. More

Suggested Articles

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.

In one of the longest studies to date in high-risk heart disease, researchers found no significant difference in death rates over more than 10 years.